Aaron C. Schmitt

发表

Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation.

S. Viatchenko‐Karpinski, J. Sudhamsu, Xiaowu Chen, 2019, ACS medicinal chemistry letters.

Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.

Adam R. Johnson, C. Eigenbrot, J. Lubach, 2016, Bioorganic & medicinal chemistry letters.

Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors.

Wen Jiang, R. Knabb, A. Rendina, 2013, Bioorganic & medicinal chemistry letters.

Design and synthesis of 6-amino-5-oxo-1,2,3,5-tetrahydro-3-indolizinecarboxylic acids as β-sheet peptidomimetics

C. Decicco, Aaron C. Schmitt, Xiaojun Zhang, 2002 .

A convenient and high yield method to prepare 4-hydroxypyroglutamic acids

Aaron C. Schmitt, Xiaojun Zhang, Wen-Qing Jiang, 2001 .

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties

Adam R. Johnson, C. Eigenbrot, J. Lubach, 2017, ACS medicinal chemistry letters.

A Convenient and High Yield Method to Prepare 4-Hydroxypyroglutamic Acids.

Aaron C. Schmitt, Xiaojun Zhang, Wen-Qing Jiang, 2001 .

Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease.

C. Decicco, Z. Wasserman, Carl P Decicco, 2003, Bioorganic & medicinal chemistry letters.

A convenient and versatile synthesis of 6,5- and 7,5-fused bicyclic lactams as peptidomimetics

Aaron C. Schmitt, Xiaojun Zhang, Wen-Qing Jiang, 2001 .

A Convenient and Versatile Synthesis of 6,5‐ and 7,5‐Fused Bicyclic Lactams as Peptidomimetics.

Aaron C. Schmitt, Xiaojun Zhang, Wen-Qing Jiang, 2001 .

Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.

S. Hymowitz, J. Lubach, K. Reif, 2015, Bioorganic & medicinal chemistry letters.

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Stephanie J. Lee, G. Hill, P. Ordentlich, 2020 .

Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases.

J. Chandrasekhar, Helen Yu, S. Wise, 2020, ACS medicinal chemistry letters.